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Background: Screening to detect prediabetes and diabetes enables early prevention and intervention. This study
describes the number and characteristics of asymptomatic, undiagnosed adults in the United States who could be
detected with prediabetes and type 2 diabetes using the American Diabetes Association (ADA) guidelines
compared to the United States Preventive Services Task Force (USPSTF) guidelines.
Methods: We developed predictive models for undiagnosed diabetes and prediabetes using polytomous logistic
regression from data on risk factors in the 2003–2010 National Health and Nutrition Examination Survey
(n = 19,056). We applied these predictive models to the 2010 Medical Expenditure Panel Survey, which contains
health care use data, to generate probabilities of undiagnosed diabetes and undetected prediabetes for each adult.
We summed individual probabilities to estimate the number of adults who would be detected with prediabetes
and/or type 2 diabetes if screened under ADA or USPSTF guidelines. We analyzed health care use patterns of
people at high risk for diabetes.
Results: In 2010, 59.1 million adults met the USPSTF screening criteria including 24.4 million people with
undetected prediabetes and 3.7 million people with undiagnosed diabetes. In comparison, among the 86.3 million
people who met the ADA screening criteria, there were 33.9 million with undetected prediabetes and 4.6 million
with undiagnosed type 2 diabetes. The ADA guidelines detected 38.9% more cases of prediabetes and 24.3% more
cases of type 2 diabetes compared to the USPSTF guidelines. Subgroup analysis showed that ADA guidelines
would detect 78% more cases of diabetes among the age 54 and younger population, in 40% more blacks, and in
more than twice as many Hispanics than USPSTF guidelines. Only 58% of adults meeting ADA guidelines and
70% meeting USPSTF guidelines had ≥ 1 primary care office visit in 2010.
Conclusions: Compared to USPSTF guidelines, ADA guidelines would screen more people and detect more cases
of both prediabetes and type 2 diabetes, though a substantial percentage of patients with undetected cases had
no contact with a primary care provider in 2010. Addressing the problem of large numbers of undetected
prediabetes and type 2 diabetes cases will require new strategies for screening.
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Type 2 diabetes is a large, costly, and growing epidemic in
the US [1]. Evidence-based interventions are available to
prevent or delay the onset of diabetes in people with pre-
diabetes [2,3] and to reduce rates of complications among
those with type 2 diabetes [4]. More than one-fourth of
the estimated 26 million Americans with diabetes remain
undiagnosed, and more than 90% of the estimated 79 mil-
lion adults with prediabetes remain undetected [5]. As
with many diseases, screening and early detection of dia-
betes and prediabetes is the first step to initiating preven-
tion and treatment interventions, and have received
considerable interest [6-8]. Screening is recommended
within a health care setting, usually by a primary care pro-
vider, so that appropriate follow-up testing and care can
be delivered [4].
US and international organizations have recommended
various guidelines for screening for type 2 diabetes in
asymptomatic adults, but these guidelines differ in the
number and types of risk factors they target [4,8-12]. The
United States Preventive Services Task Force (USPSTF),
an independent panel of experts that conducts scientific
reviews of preventive health care services, recommends
screening only adults with sustained hypertension (either
treated or untreated) greater than 135/80 mm Hg [8]. In
comparison, the American Diabetes Association (ADA)
recommends broader screening criteria by targeting every-
one age 45 and older as well as overweight adults of any
age who have additional risk factors, including family
history of diabetes, being a member of a high-risk racial/
ethnic population, physical inactivity, high cholesterol,
signs of insulin resistance (such as acanthosis nigricans),
polycystic ovarian syndrome, history of gestational dia-
betes, or previous diagnosis of prediabetes, as well as hav-
ing hypertension [4]. For adults age 45 and older with
normal test results, the ADA recommends repeat testing
at least every three years. Other organizations have also
endorsed guidelines that encompass multiple risk factors
to screen for asymptomatic adults—including the Ameri-
can Heart Association, the American College of Physicians,
The Endocrine Society, and the Veterans Health Adminis-
tration [13-16]. While USPSTF guidelines are designed to
detect diabetes, ADA guidelines are designed to detect
both diabetes and prediabetes.
The number of people screened and detected with
diabetes or prediabetes in a given population will differ
depending on which guidelines are followed. For ex-
ample, analysis of an ambulatory population seen at
one large physician practice found following the ADA
guidelines would detect 50% more cases of undiag-
nosed diabetes than would be detected if following the
USPSTF guidelines [17]. A study modeling simulated
screening strategies found that screening based on
USPSTF guidelines identified fewer people with diabetescompared to screening initiated at age 45, as recom-
mended by the ADA [18].
Our study investigates two sets of questions with re-
spect to USPSTF and ADA screening guidelines: (1)
How many people in the US in 2010 could have been
screened and identified with diabetes and prediabetes
under each set of guidelines, and what are the character-
istics of populations detected with prediabetes and dia-
betes? (2) What are the health care use patterns of
adults at high risk for prediabetes or diabetes, and how




We used the 2003–2010 waves of the National Health and
Nutrition Examination Survey (NHANES), a major nation-
ally representative survey of the US non-institutionalized
population, to develop predictive models for undiagnosed
diabetes and undetected diabetes [19]. NHANES includes
detailed health information and characteristics, including
whether a respondent has ever been told by a health care
professional that he or she has diabetes or prediabetes. A
random sample of approximately one-third of NHANES
adults receives laboratory tests to provide more detailed
descriptions of their health status. Comparison of self-
reported glycemic status with laboratory tests provides an
opportunity to develop a clinically based model of undiag-
nosed glycemic disease. These laboratory tests include
hemoglobin A1c (HbA1c), fasting plasma glucose (FPG),
and/or oral glucose tolerance test (OGTT). Many individ-
uals receive more than one test type.
We used the 2010 Medical Expenditure Panel Survey
(MEPS) to analyze health care use patterns and estimate
the number of people whose diabetes or prediabetes
could be detected using the ADA and USPSTF screening
guidelines [20]. Like NHANES, MEPS collects detailed
information on patient characteristics, health-related be-
havior, and presence of chronic conditions. MEPS does
not contain lab values but does collect detailed informa-
tion on health care use patterns for each participant over
a one-year period. MEPS contains a self-reported indica-
tion of previous diabetes diagnosis, but includes no data
on previous prediabetes diagnosis. Both surveys contain
sample weights to generalize from the sample to the US
population, and weights were used in the regression ana-
lyses and to generate summary statistics.
Selection and exclusion criteria
Exclusion criteria for our analysis included women who
indicated they were pregnant at the time of their
NHANES lab test (n = 425), as well as people who indi-
cated that they had previously been told by a health care
professional that they have diabetes or for whom there
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This provides a sample of 19,056 individuals with lab
results— including 9,855 who received only the HbA1c
test; 5,809 who received all three tests (HbA1c, FPG,
and OGTT); 3,362 who received both HbA1c and FPG;
18 who received FPG and OGTT; seven who received
only FPG; and five who received both HbA1c and OGTT.
We applied similar exclusion criteria for the MEPS ana-
lysis, restricting the population to non-pregnant adults age
18 and older without diagnosed diabetes (n = 21,774).
Definitions of key variables
Using lab values in NHANES, diabetes was defined as
OGTT ≥ 200 at two hours or FPG ≥ 126 or HbA1c ≥ 6.5;
prediabetes was defined as 199 ≥OGTT ≥ 140 at two
hours, 125 ≥ FPG ≥ 100, or 6.4 ≥HbA1c ≥ 5.7 [4]. We
categorized people as having diabetes if any of their lab
tests were in the diabetes range. For individuals not cate-
gorized as having diabetes, we categorized them as hav-
ing prediabetes if any of their test results were in the
prediabetes range. A limitation of NHANES, discussed
later, is that no follow-up confirmatory test is available,
and research suggests that using a single test can result
in false positives or negatives [21].
For modeling purposes, we placed each NHANES
adult into one of four categories: undiagnosed diabetes,
diagnosed prediabetes, undetected prediabetes, or nor-
mal lab levels. Undiagnosed diabetes and undetected
prediabetes were defined by a negative response to the
question “have you ever been told by a health care pro-
fessional that you have diabetes or prediabetes?” and a
positive finding for diabetes or prediabetes on the lab
test results [22].
We selected explanatory variables for the regression
analysis (described later) based on established [9,10,23-27]
risk factors for diabetes that are common to the NHANES
and MEPS databases, as well as variables associated with
greater access to or use of health care services. All vari-
ables were coded as dichotomous indicators (characteristic
applies = 1, else = 0), with the exception of family income
(measured continuously in thousands of 2010 dollars).
Variables used were sex; six age groups (18–34, 35–44,
45–54, 55–64, 65–74, and 75+ years); race/ethnicity (non-
Hispanic white, non-Hispanic black, non-Hispanic other,
and Hispanic); previous diagnoses or history of asthma,
arthritis, heart attack, stroke, cancer, hypertension, high
cholesterol, and cardiovascular disease; current smoker;
body weight defined by body mass index [28]—normal
(BMI < 25), overweight (25 ≤ BMI < 30), or obese (30 ≤
BMI); has medical insurance; is insured through Medicaid;
and survey year. While arthritis and asthma are not recog-
nized risk factors for diabetes, we included these indica-
tors because patients with these conditions have more
annual visits with health care providers, which couldincrease the number of opportunities for screening. In-
cluding these two conditions might also result in earlier
identification of diabetes or prediabetes if such patients
were treated with corticosteroids, in light of the known
hyperglycemic effect of these medications. Our analysis
omitted ADA screening risk factors for which data are un-
available in NHANES or MEPS (family history of diabetes,
polycystic ovarian syndrome, or gestational diabetes).
Statistical analysis plan
Using NHANES data for those individuals not previously
diagnosed with diabetes (n = 19,056), we estimated a
polytomous logistic predictive model. This regression
approach allowed us to model a dependent variable with
three values: normal glucose levels, prediabetes (both di-
agnosed and undiagnosed), and undiagnosed diabetes,
and thus provided estimated risks for both diabetes and
prediabetes [29]. We applied this predictive model from
NHANES to each adult in MEPS to generate individual
probabilities of undiagnosed diabetes and prediabetes
based on each person’s demographic, health, and socio-
economic characteristics.
Separate from the polytomous logistic regression, we
used logistic regression to quantify the relationship be-
tween patient characteristics and diagnosed prediabetes
(n = 676). We used the same explanatory variables as de-
scribed previously, with the dependent variable indicat-
ing previous detection of prediabetes. We applied this
second regression to the MEPS sample to estimate each
person’s probability of previous prediabetes detection.
The total probability of prediabetes minus the probabil-
ity of detected prediabetes provided an estimated prob-
ability of undetected prediabetes for each person.
We then identified adults in the MEPS who would be
screened under the USPSTF and ADA screening guide-
lines and summed their predicted probabilities for un-
detected prediabetes and undiagnosed diabetes to provide
estimates of the potential number of people in the US who
could be detected under each screening guideline. Con-
sider, for example, an individual with a predicted proba-
bility of 0.3 for undetected prediabetes and 0.1 for
undiagnosed diabetes, and with a sample weight of 1000
(meaning this person represents 1,000 people in the US
population). If this sample person met the screening cri-
teria, then he or she represents 1,000 people screened, 300
people (0.3 × 1,000) in whom prediabetes would be de-
tected, and 100 people (0.1 × 1,000) in whom diabetes
would be diagnosed.
When modeling the ADA screening guidelines (using
those risk factors available in MEPS), if a person met the
criteria only because he or she was over age 45 (that is,
was not overweight or had no other risk factors), we
modeled this person as having a one-in-three probability
of being screened during the year. This assumption was
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over age 45 with no risk factors should be re-screened
every three years.
We then used MEPS to analyze health care use patterns
of people who met the ADA and USPSTF screening cri-
teria to estimate the number of detection (screening) op-
portunities that exist under current patterns of usage.
To validate the predictive modeling approach, we ran-
domly divided the NHANES sample into two groups
with 9,528 observations each. We estimated a predictive
model for prediabetes and undiagnosed diabetes with
one group, and then applied the model to the second
group. For the second group, we compared the sum of
predicted probabilities of prediabetes and undiagnosed
diabetes with the clinical indication of prediabetes or un-
diagnosed diabetes. The analysis suggests that the pre-
dictive modeling approach reliably estimated total cases
of prediabetes and undiagnosed diabetes in the popula-
tion by age group. Regressions estimated with both sub-
sets of NHANES produced similar coefficients, so we
used the full NHANES sample to generate the results
presented in this paper.
Results
NHANES sample and predictive model
Summary statistics for the NHANES sample are consistent
with the published literature and are summarized in
Table 1. Approximately 90% of prediabetes cases were un-
detected. Characteristics associated with higher odds of
having undiagnosed diabetes or prediabetes include male,
older age, minority race and Hispanic, hypertension, hyper-
cholesterolemia, cardiovascular disease, smoking, and ex-
cess body weight (Table 2) [5]. Having medical insurance
and higher annual family income are associated with lower
odds of prediabetes and undiagnosed diabetes. Many of
the factors associated with prediabetes and undiagnosed
diabetes are the same as those associated with diagnosed
diabetes. Variation across NHANES years could be due in
part to changes in laboratory methodology across different
NHANES years.
Applying the predictive model to MEPS adults who do
not have diagnosed diabetes produced probabilities of
undiagnosed diabetes ranging from 0.3% to 26.2%.
Whereas the person among the MEPS sample with the
lowest predicted probability of undiagnosed diabetes is a
young, non-Hispanic white, high-income female with no
history of chronic conditions and no known risk factors
for diabetes, the person with the highest predicted prob-
ability is older, male, non-Hispanic other (non-black) mi-
nority, obese, and with a history of hypertension, high
cholesterol, and cardiovascular disease.
Characteristics associated with statistically higher prob-
ability of undiagnosed diabetes (Figure 1) and prediabetes
(Figure 2) include older age, excess body weight, racial orethnic minority, male, hypertension, cardiovascular dis-
ease, dyslipidemia, and smoking. These characteristics
substantially overlap risk factors in the ADA guidelines.
Being obese (versus normal weight) is associated with a
4.8 percentage point increase in probability of undiag-
nosed diabetes among a population age 45 to 54 with
population mean values for the other risk factors.
USPSTF vs. ADA guidelines: Diabetes and prediabetes
cases detected
The US had approximately 7 million adults with undiag-
nosed diabetes and 79 million with undetected prediabe-
tes in 2010 [5]. Our analysis suggests that 59.1 million
adults in the US meet the USPSTF screening guidelines,
and screening of all these individuals would detect 3.7
million people with diabetes and 24.4 million with predi-
abetes—or about half (53%) the cases of undiagnosed
diabetes and one-third (31%) of the cases of undetected
prediabetes (Tables 3 and 4). Such findings are consist-
ent with research suggesting that approximately half of
the people with undiagnosed diabetes do not meet
USPSTF screening guidelines [12]. In contrast, 86.3 mil-
lion adults meet ADA guidelines (assuming that one in
three adults age 45 or older without other risk factors
were screened in a given year), and screening these
adults would detect 4.6 million people with diabetes and
33.9 million people with prediabetes.
ADA guidelines would detect nearly 1.5 million dia-
betes cases that would be missed under USPSTF guide-
lines (Table 3). USPSTF guidelines would detect 587,000
diabetes cases that would be missed under ADA guide-
lines in the initial year of fully implementing the latter
guidelines, but these include adults over age 45 who
would be screened in subsequent years. Under the ADA
guidelines, within three years all adults age 45 and older
would be screened.
ADA guidelines identify substantially more individuals
in minority populations as having diabetes and prediabe-
tes than do USPSTF screening guidelines. ADA guide-
lines detect 40% more blacks and more than twice as
many Hispanics with diabetes relative to USPSTF guide-
lines (Table 3). Nearly 80% more blacks and more than
three times as many Hispanics would be detected with
prediabetes using ADA guidelines compared to USPSTF
guidelines (Table 4). Among Hispanics, USPSTF guide-
lines miss 5.4 million people with prediabetes who
would be detected using ADA guidelines. In comparison,
ADA guidelines would miss only 408,000 with prediabe-
tes that would be detected using USPSTF guidelines.
USPSTF guidelines both screen and detect a signifi-
cantly older population. Whereas 35% of people with
diabetes detected under ADA guidelines are age 65 and
older, 46% of people detected under USPSTF guidelines
are age 65 or older.
Table 1 NHANES descriptive statistics by diabetes population (% or $)
Patient characteristics Normal glucose






diabetes (n = 1,056)
Diagnosed
diabetes (n = 2,296)
Male 45 55 42 55 50
Age category
Age 18-34 47 17 11 5 4
Age 35-44 18 15 15 12 7
Age 45-54 13 19 18 16 16
Age 55-64 9 18 21 21 26
Age 65-74 6 15 20 23 28
Age 75+ 7 15 16 24 19
Race and ethnicity
Non-Hispanic white 73 68 72 68 63
Non-Hispanic black 10 12 11 11 16
Non-Hispanic other 5 7 7 5 7
Hispanic 12 13 9 15 13
Has been diagnosed with
Asthma 13 12 19 13 16
Arthritis 17 30 46 37 49
History of heart attack 2 5 8 8 12
History of stroke 2 4 5 5 11
History of cancer/
malignancy
6 10 15 14 14
High blood pressure 19 38 56 54 70
High cholesterol 18 33 50 40 57
Cardiovascular disease 3 8 13 14 22
Current smoker 21 21 16 20 17
Body weight status 41 25 20 17 17
Normal 41 25 20 17 17
Overweight 33 36 31 31 28
Obese 26 39 50 52 55
Median annual family
income (thousands of US
$)
40 35 30 30 30
Has medical insurance 74 76 85 80 87
Insured through Medicaid 5 6 8 7 10
NHANES survey wave
Years 2003-4 28 17 9 14 21
Years 2005-6 26 20 22 19 20
Years 2007-8 22 31 33 34 30
Years 2009-10 25 32 36 33 29
Source: Analysis of 2003–2010 National Health and Nutrition Examination Survey. Note: Body weight status is defined by body mass index (BMI): normal (BMI < 25),
overweight (25 ≤ BMI < 30), and obese (30 ≤ BMI).
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diabetes or prediabetes
The above MEPS analysis illustrates the number of people
in the US who could be screened and for whom diabetes
or prediabetes could be detected applying USPSTF andADA guidelines population-wide. In general, though,
screening occurs opportunistically when patients visit a
health care provider during an office visit, outpatient or
emergency visit, or when hospitalized. Therefore, we
analyzed the health care use patterns for people at high
Table 2 Odds ratios from NHANES regressions
Effect Undiagnosed diabetes and total
prediabetes†
Diagnosed prediabetesŧ Diagnosed diabetesŧ
Male 1.44* 0.80* 1.16*
Age 18–34 (comparison)
Age 35-44 1.93* 2.01* 2.09*
Age 45-54 3.70* 2.04* 4.12*
Age 55-64 5.52* 2.50* 5.46*
Age 65-74 7.03* 2.43* 7.10*
Age 75+ 8.89* 1.90* 5.79*
Non-Hispanic white (comparison)
Non-Hispanic black 1.61* 1.07 1.92*
Non-Hispanic other 1.97* 1.63* 2.23
Hispanic 1.61* 1.08 2.22*
Has been diagnosed with
Asthma 1.05 1.51* 1.10*
Arthritis 1.02 1.45* 1.22*
History of heart attack 1.00 1.47 1.11
History of stroke 1.06 1.07 1.82*
History of cancer/malignancy 1.03 1.19 1.07
High blood pressure 1.36* 1.81* 2.15*
High cholesterol 1.18* 1.56* 1.90*
Cardiovascular disease 1.18* 1.14 1.87*
Current smoker 1.17* 0.72* 0.95
Overweight vs. normal weight 1.60* 1.30* 1.22*
Obese vs normal weight 2.96* 1.92* 2.79*
Annual family income (thousands of
US$)
0.998* 0.998 0.994*
Has medical insurance 0.81* 1.16 1.22
Insured through Medicaid 1.17 1.11 1.24*
Survey Years 2003–4 (comparison)
Years 2005-6 1.42* 2.86* 0.99
Years 2007-8 2.43* 3.39* 1.09
Years 2009-10 2.20* 3.79* 1.04
Sample size 509/7,027/11,520 UDM/PDM/normal 676/18,380 PDM/non-diabetic 2,296/19,056 DDM/non-DDM
Model goodness-of-fit statistics
Percent concordant 76.2 76.1 83.0
Percent discordant 23.5 22.5 16.6
Percent tied 0.4 1.4 0.4
Number of pairs matched 90,391,463 12,424,880 43,752,576
Somers’ D 0.529 0.535 0.664
c-statistic 0.764 0.768 0.832
Source: Analysis of 2003–2010 National Health and Nutrition Examination Survey. Notes: Body weight status is defined by body mass index (BMI): normal
(BMI < 25), overweight (25 ≤ BMI < 30), and obese (30 ≤ BMI). † Polytomous logistic regression. ŧ Usual logistic regression. * Odds ratio statistically different from
1.0 at the 0.05 level. DDM = diagnosed diabetes, UDM = undiagnosed diabetes, PDM = prediabetes.






















Black (vs NH white)
Other (vs NH white)









Change in Prediabetes Probability
(relative to "average" person age 45-54)
Figure 2 Standardized effect on probability of prediabetes and diabetes controlling for other patient characteristics. Note: This figure is
based on patient risk for prediabetes assuming population averages for all characteristics except the characteristic of interest (where the presence





















Black (vs NH white)
Other (vs NH white)









Change in Undiagnosed Diabetes Probability
(relative to "average" person age 45-54)
Figure 1 Standardized effect on probability of undiagnosed diabetes controlling for other patient characteristics. Note: This figure is
based on patient risk for undiagnosed diabetes assuming population averages for all characteristics except the characteristic of interest (where
the presence of the characteristic is compared to the absence of that characteristic).
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Table 3 Characteristics and number of adults with diabetes detected under ADA and USPSTF guidelines (thousands of
people)
Patient characteristics ADA alone USPSTF alone Either ADA or USPSTF ADA but not USPSTF USPSTF but not ADA
Age category
<45 770 324 791 467 22
45-54 955 643 1,015 372 60
55-64 1,283 1,039 1,397 358 115
65+ 1,631 1,729 2,021 292 390
Sex
Men 2,661 2,039 2,924 885 264
Women 1,978 1,696 2,300 604 322
Race and ethnicity
Non-Hispanic white 2,757 2,519 3,161 642 404
Non-Hispanic black 831 589 900 311 69
Non-Hispanic other 214 237 278 42 64
Hispanic 837 391 886 494 49
Body weight status
Overweight 2,036 1,298 2,036 739 0
Obese 2,603 1,852 2,603 750 0
Diagnosed hypertension 3,150 3,736 3,736 0 586
Household income quartile
First 1,073 823 1,217 352 136
Second 1,087 934 1,250 314 153
Third 1,107 928 1,230 348 145
Fourth 1,372 1,051 1,528 475 152
Insured 3,853 3,280 4,390 1,110 537
Employed 2,592 1,753 2,785 1,031 193
Highest education level
Less than college 3,116 2,522 3,512 990 396
Baccalaureate degree 700 550 781 232 81
Graduate degree 797 646 899 254 102
Region
Northeast 834 676 949 273 115
Midwest 968 840 1,087 247 119
South 1,792 1,424 2,011 588 220
West 1,046 796 1,178 382 132
Metropolitan area 3,873 3,063 4,357 1,294 484
Total 4,639 3,735 5,224 1,489 587
Notes: Population analyzed is 202 million non-diabetic, non-pregnant adults age 18 or older in the US in 2010. Body weight status is defined by body mass index
(BMI): overweight (25 ≤ BMI < 30) and obese (30 ≤ BMI). ADA = American Diabetes Association. USPSTF = US Preventive Services Task Force.
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ticular, patterns of visiting a primary care provider in
2010—to understand what segment of the population
had the opportunity to be screened during that year.
Across the entire US population of adults without di-
agnosed diabetes and excluding pregnant women, our
MEPS analysis suggests that 67% of visits within thehealth care system were office visits to specialist pro-
viders; 22% were visits to primary care providers; and
the rest consisted of hospital outpatient visits (7%),
emergency department visits (3%) and inpatient hospital-
izations (1%).
Strikingly, we found that having a greater number of
annual visits within the health care system is positively
Table 4 Characteristics and number of adults with prediabetes detected under ADA and USPSTF guidelines (thousands
of people)
Patient characteristics ADA alone USPSTF alone Either ADA or USPSTF ADA but not USPSTF USPSTF but not ADA
Age category
<45 9,973 3,706 10,324 6,617 351
45-54 7,826 4,995 8,557 3,562 731
55-64 8,057 6,378 9,204 2,826 1,147
65+ 8,071 9,328 11,233 1,905 3,162
Sex
Men 19,378 12,977 21,720 8,743 2,342
Women 14,549 11,430 17,598 6,168 3,049
Race and ethnicity
Non-Hispanic white 19,228 17,250 23,126 5,876 3,898
Non-Hispanic black 6,206 3,477 6,799 3,322 593
Non-Hispanic other 1,122 1,297 1,613 316 491
Hispanic 7,371 2,383 7,779 5,396 408
Body weight status
Overweight 17,971 9,536 17,971 8,435 0
Obese 15,957 9,481 15,957 6,476 0
Diagnosed hypertension 19,016 24,407 24,407 0 5,391
Household income quartile
First 7,078 4,830 8,338 3,369 1,133
Second 7,487 5,572 8,828 3,118 1,308
Third 8,336 6,338 9,568 3,509 1,344
Fourth 10,952 7,668 12,584 4,914 1,606
Insured 26,977 21,133 31,827 10,694 4,850
Employed 22,269 13,307 24,399 11,092 2,129
Highest education level
Less than college 22,342 15,903 25,883 9,979 3,540
Baccalaureate degree 5,414 3,870 6,210 2,339 796
Graduate degree 5,957 4,500 6,964 2,463 1,007
Region
Northeast 6,006 4,421 7,051 2,630 1,045
Midwest 6,894 5,541 8,010 2,469 1,116
South 13,225 9,335 15,285 5,950 2,060
West 7,803 5,110 8,972 3,862 1,169
Metropolitan area 15,297 10,904 17,873 6,970 2,576
Total 33,927 24,407 39,318 14,910 5,391
Note: Population analyzed is 202 million non-diabetic, non-pregnant adults age 18 or older in the US in 2010. Body weight status is defined by body mass index
(BMI): overweight (25 ≤ BMI < 30) and obese (30 ≤ BMI). ADA = American Diabetes Association. USPSTF = US Preventive Services Task Force.
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betes, suggesting that multiple opportunities for diabetes
detection are being missed (Table 5). For example, adults
having a less than 5% probability for undiagnosed dia-
betes averaged 4.7 visits in 2010; adults with 5%-10%
probability averaged 8.8 visits; and adults with a greater
than 10% probability of undiagnosed diabetes averaged10.7 visits. Adults meeting the ADA screening criteria
averaged 6.9 visits, while adults meeting the USPSTF
screening criteria averaged 9.1 visits. For comparison,
people with diagnosed diabetes averaged 11.7 visits.
While averages can be sensitive to outliers, across all
the care delivery settings modeled there is a clearly
observed relationship between patient probability of
Table 5 Health care use patterns by predicted undetected diabetes and prediabetes status
Average annual visits















<0.05 155,511 1.00 3.19 0.29 0.13 0.05 4.67
0.05 to <0.10 37,462 2.01 5.72 0.67 0.21 0.15 8.76
≥0.10 10,652 2.39 6.32 1.51 0.22 0.22 10.67
Predicted probability of
undetected prediabetes
<0.10 13,904 0.93 2.62 0.16 0.11 0.03 3.85
0.10 to <0.15 21,019 0.69 2.09 0.19 0.13 0.03 3.12
0.15 to <0.20 19,964 0.67 2.69 0.24 0.11 0.03 3.74
0.20 to <0.25 17,790 0.86 2.79 0.22 0.15 0.04 4.06
0.25 to <0.30 21,049 0.97 3.45 0.40 0.14 0.06 5.01
0.30 to <0.35 17,511 1.26 4.12 0.72 0.15 0.09 6.34
0.35 to <0.40 23,528 1.59 4.72 0.46 0.18 0.10 7.05
≥0.40 68,860 1.75 4.91 0.59 0.18 0.13 7.56
ADA 86,292 1.59 4.39 0.58 0.18 0.11 6.85
USPSTF 59,064 2.14 5.77 0.79 0.23 0.16 9.09
Diagnosed diabetes 20,458 2.81 7.21 1.08 0.31 0.28 11.69
Note: Analysis of the 2010 Medical Expenditure Panel Survey. 1Population analyzed is 202 million non-diabetic, non-pregnant adults age 18 or older in the US in
2010. Representative sample of the non-institutionalized population in the US excluding pregnant women. 2Office visit to a general or family practice or general
internal medicine practice. 3Visits to non-primary care providers (excluding obstetrician-gynecologist visits). 4Hospital outpatient or emergency visit, or
hospitalization for any reason.
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annual visits.
Opportunities to detect diabetes during primary care
office visits
We estimate that the US adult population without diag-
nosed diabetes made approximately 256 million visits to a
primary care provider in 2010. In addition, 58% (50 million
people) of adults meeting the ADA diabetes screening
criteria had at least one primary care visit in 2010, and
among these were an estimated 3.1 million patients with
undiagnosed diabetes and 20.4 million with undetected
prediabetes (Table 6). Of those adults meeting the USPSTFTable 6 Opportunities for screening during primary care offic
Applying screening guidelines
Number of patients with at least one primary care visit
Percent of patients with at least one primary care visit
Potential cases of diabetes to detect
Potential cases of prediabetes to detect
Note: Estimates derived from analysis of the 2010 Medical Expenditure Panel Surve
prediabetes for 202 million non-diabetic, non-pregnant adults age 18 or older in th
practice or general internal medicine practice. Total primary care visits in 2010 by a
diagnosed diabetes) is 256.3 million.criteria, 70% (41.5 million people) had at least one pri-
mary care visit in 2010, and among these were 2.8 mil-
lion cases of undiagnosed diabetes and 17.3 million
cases of undetected prediabetes.
Of the estimated 4.6 million adults with undiagnosed
diabetes meeting the ADA screening criteria, 66% could
have been identified in 2010 if the criteria had been ap-
plied during visits to a primary care provider. Of the 3.7
million adults in the US who have undiagnosed diabetes
and who meet the USPSTF screening criteria, 74% could
have been identified in 2010 if those criteria had been
applied during visits to a primary care provider. For
comparison, the CDC estimates that 1.9 million peoplee visits





y using predicted probability of patient having undetected diabetes or
e US in 2010. Primary care visits identified as visits to a general or family
dults age 18 and older (excluding pregnant patients and patients with
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suggesting that large numbers of asymptomatic adults
who meet screening criteria are not being tested.
Discussion
In this study, we compared two strategies to diagnose
currently undiagnosed cases of prediabetes and type 2
diabetes. Our research aimed to answer two sets of ques-
tions: (1) How many people in the US in 2010 could
have been screened and identified with diabetes and
prediabetes under ADA and USPSTF guidelines, and
what are the characteristics of populations detected with
prediabetes and diabetes? (2) What are the health care
use patterns of adults at high risk for prediabetes or dia-
betes, and how does this affect the ability of primary
care providers to implement USPSTF and ADA guide-
lines? These findings have implications for identifying
the most efficient screening strategies.
Comparison of ADA and USPSTF guidelines to address
the first set of questions suggests three key implications:
1. ADA guidelines detect more people with diabetes
and prediabetes compared to USPSTF guidelines,
but the latter require slightly fewer people to be
screened for each diabetes case detected. ADA
guidelines would screen 19 adults for each case of
diabetes detected, whereas USPSTF would screen 16
adults for each case detected. In other words, ADA
appears to be more effective, while USPSTF may be
more efficient. The relative efficiency of the two
alternative strategies will depend on the costs of
screening and the net effect of screening on medical
care costs. Screening costs and forecasts of medical
cost savings from alternative screening strategies are
beyond the scope of the current paper. It is
important to note, however, that the detection rates
of the two screening options considered here are not
very different when considering both diabetes and
prediabetes. ADA guidelines result in 2.2 people
screened per case detected while USPSTF guidelines
result in 2.1 people screened per case detected.
Because ADA guidelines screen more people, ADA
guidelines identified 38.9% more undetected cases of
prediabetes and 24.3% more undetected cases of
type 2 diabetes than did the USPSTF guidelines.
2. ADA guidelines detect more people with diabetes
and prediabetes among racial and ethnic minorities
and low-income households that historically have
had less access to the health care system.
3. The population detected under ADA guidelines is
younger than the population detected under
USPSTF guidelines. The health, economic, and
quality of life implications of early detection and
intervention among younger populations could bequite different from detection among older
populations. The lifetime direct medical costs of
diabetes for men and women diagnosed between the
ages of 25–44 are more than twice the lifetime cost of
people diagnosed after age 65—reflecting the fact that
people who develop diabetes at earlier ages have more
time to develop complications and incur diabetes-
related costs [30]. Such findings suggest the potential
for substantial lifetime economic benefits to detection
and treatment of diabetes at younger ages.
On the question of health care use patterns, our over-
all findings have two key implications. Our study identi-
fied two unique target populations for diagnostic testing:
(1) a population in poor health with many contacts with
the health care system but no apparent diagnostic test-
ing for prediabetes or type 2 diabetes; and (2) a popula-
tion who, regardless of health status, had no apparent
contact with the health care system and therefore no op-
portunity for diagnostic testing.
1. The first population represents a missed
opportunity, especially given the number of primary
care visits reported by these patients. We will leave
to others whether this problem is best addressed
through increased patient or provider education,
changes in preventive screenings, or other
combination of strategies. What is clear is that the
missed opportunity is substantial.
2. The second population, those without contact with
the health care system, will require a more
innovative approach. Strategies would need to be
tested and further research conducted to better
identify these people. For example, is their lack of
contact due to a lack of health insurance coverage,
low income, or cultural reasons? A more refined
identification of these people will allow more
effective strategies to be developed. One thing is
clear: the traditional office-based approach will not
work for people who seldom visit a doctor’s office.
Study limitations and areas for future research
This study takes advantage of large, nationally represen-
tative data sources to simulate the likely screening and
detection implications of ADA and USPSTF screening
criteria. The regression models that quantify the rela-
tionship between patient characteristics and probability
of undiagnosed diabetes and prediabetes show strong
goodness of fit, and validation activities suggest the
models are robust.
One limitation of this study is the omission of some
diabetes risk factors (such as a history of gestational dia-
betes or family history of diabetes) due to a lack of data
in the MEPS. Diagnosed prediabetes is excluded as an
Dall et al. Population Health Metrics 2014, 12:12 Page 12 of 14
http://www.pophealthmetrics.com/content/12/1/12explanatory variable from our predictive model because
diagnosed prediabetes status is unavailable in the MEPS.
Another limitation is that NHANES does not have
follow-up testing, so we were unable to model the risk of
false positives or false negatives from screening [31]. The
estimated prediction equations, though, are designed to
identify population subsets that are at high risk for un-
detected prediabetes or undiagnosed diabetes (rather than
identify individual people who should be screened).
This study uses multiple diagnostic tests in NHANES
(HbA1c, FPG, and OGTT) to identify people with un-
detected diabetes and prediabetes for use in the logistic
regression analysis. Almost 100% of the sample received
an HbA1c test, half (48%) received an FPG test, and 31%
received an OGTT test. The CDC (2011 Diabetes Fact
Sheet) uses either FPG or HbA1c in the prediabetes or
diabetes range to estimate national prevalence of predia-
betes and undiagnosed diabetes—stating that HbA1c
and FPG are used because these tests are most often
used in clinical practice [5]. CDC notes that use of all
three tests, a subset of tests, or individual tests produces
different estimates of total prevalence of diabetes and
prediabetes.
We conducted sensitivity analyses on the predictive
model goodness of fit and use of different diagnostic tests
to define prediabetes and undetected diabetes for the re-
gression analysis. We find that use of all three diagnostic
tests to define diabetes or prediabetes status produced
slightly higher regression intercept estimates than using
HbA1c and FPG, but produced similar estimates of odds
ratios and prediction outcomes. (We scaled each individ-
ual’s predicted probabilities of undiagnosed diabetes and
prediabetes by 0.975 so that national totals matched
CDC’s national estimates for 2010 of 79 million with pre-
diabetes and 7 million with undiagnosed diabetes.) Using
only HbA1c to define diabetes or prediabetes status pro-
duced lower regression intercept estimates and a stronger
age and racial/ethnic minority effect on probability of pre-
diabetes or undetected diabetes. In terms of overall study
findings, using prediction equations based only on HbA1c
identified an older population with prediabetes and un-
diagnosed diabetes than reported in this paper. CDC notes
that “Research is ongoing to ascertain the best use of
laboratory blood tests to detect people who may have
prediabetes and to improve the understanding of who has
prediabetes” [5].
While this analysis focused on the potential to detect
diabetes and prediabetes cases in 2010, the full implica-
tions of implementing ADA guidelines would take more
than one year to manifest, as ADA guidelines call for
asymptomatic adults age 45 without risk factors to be
screened every three years.
Future research might explore the health, economic,
and quality of life implications of detecting diabetesamong different subsets of the population (such as youn-
ger versus older adults) to better understand the impli-
cations of alternative screening guidelines that differ in
their ability to detect diabetes and prediabetes among se-
lect populations.
Because patients with risk factors for diabetes (such as
obesity and hypertension) tend to have greater medical
needs, a disproportionate number of patients seeking
care in some settings, such as hospital emergency de-
partments, are likely to be at high risk for undiagnosed
diabetes or prediabetes. Work by Silverman et al., for ex-
ample, suggests the prevalence of undiagnosed diabetes
and undetected prediabetes among patients admitted to
emergency departments for acute illness is 10.5% and
31.9%, respectively [32]. Still, a large study of 2,260 indi-
viduals diagnosed with type 2 diabetes found that 88.3%
were diagnosed by a family doctor/general practitioner,
4.4% by an endocrinologist, 0.5% by a cardiologist, 0.7%
by a neurologist, and 6% by another specialist [33]. This
finding highlights the importance of primary care pro-
viders in diagnosis of diabetes.
Future research might explore in more depth the
health care use patterns of people at high risk for un-
diagnosed diabetes and why, despite the high volume of
care being provided, there are still many people whose
diabetes and prediabetes remains undiagnosed.
While this study shows that USPSTF guidelines are
slightly more efficient in identifying people with diabetes
(in terms of number of people screened to detect each
case of diabetes), ADA guidelines are more effective in
terms of identifying more people. Ongoing research to
investigate the cost-effectiveness of ADA versus USPSTF
screening guidelines, in terms of the cost to screen and
the cost of intervention among the prediabetic popula-
tion to prevent or delay diabetes onset and sequelae,
would be an essential component for policy decisions in
this area.
Conclusions
Early detection is the first step to provide counseling
and well-organized, evidence-based intervention to pre-
vent or delay the onset of diabetes among those with
prediabetes, and to prevent or delay the onset of compli-
cations among people with diabetes. Relative to USPSTF
guidelines, ADA guidelines identify more people with
prediabetes and undiagnosed diabetes (especially more
minority cases) and a younger population that allows for
the potential for more effective improvements in quality
of life and potentially improved outcomes. The health
care use patterns of people at high risk for undiagnosed
diabetes and prediabetes combined with the high preva-
lence of undiagnosed cases suggest that many opportun-
ities for diagnosis are being missed. Many high-risk
adults do not receive regular care from a primary care
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care system technology, health care use patterns, and
medical practice continue to evolve, more effective and
efficient methods and criteria for diabetes screening in
asymptomatic adults should be sought.
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